Evidence map›Paper›PMID 38627785›Full record

ArticleBMC biology2024

GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer.

Xuejie Wang, Feng Bai, Xiong Liu, Bin Peng, Xingzhi Xu, Hongquan Zhang, Li Fu, Wei-Guo Zhu, Bin Wang, Xin-Hai Pei

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Xuejie WangGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center, Marshall Laboratory of Biomedical Engineering, The First Affiliated Hospital, Shenzhen University Medical School, Shenzhen, 518060, China.
Feng BaiDepartment of Pathology, Shenzhen University Medical School, Shenzhen, 518060, China.
Xiong LiuGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center, Marshall Laboratory of Biomedical Engineering, The First Affiliated Hospital, Shenzhen University Medical School, Shenzhen, 518060, China.
Bin PengGuangdong Key Laboratory for Genome Stability & Disease Prevention and International Cancer Center and Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen, 518060, China.
Xingzhi XuGuangdong Key Laboratory for Genome Stability & Disease Prevention and International Cancer Center and Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen, 518060, China.
Hongquan ZhangProgram for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Li FuDepartment of Pharmacology, Shenzhen University Medical School, Shenzhen, 518039, China.
Wei-Guo ZhuDepartment of Biochemistry and Molecular Biology, International Cancer Center, Shenzhen University Medical School, Shenzhen, 518060, China.
Bin WangDepartment of General Surgery, Shenzhen Children's Hospital, Shenzhen, 518038, China. szwb1967@126.com.
Xin-Hai PeiGuangdong Provincial Key Laboratory of Regional Immunity and Diseases, International Cancer Center, Marshall Laboratory of Biomedical Engineering, The First Affiliated Hospital, Shenzhen University Medical School, Shenzhen, 518060, China. peixinhai@szu.edu.cn.ORCID http://orcid.org/0000-0001-6441-1691
Shenzhen University Health Science Center · CNUniversity of Miami · USPeking University · CNShenzhen Children's Hospital · CNShenzhen University · CN

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2019A1515011343Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515011145Natural Science Foundation of Shenzhen City 20220810144854005Shenzhen Science and Technology Innovation Program JCYJ20190808115603580Shenzhen Science and Technology Innovation Program JCYJ20190808165803558Shenzhen Science and Technology Program JCYJ20210324094611032SZU Top Ranking Project 860-00000210
6 · The paper itself

Abstract

backgroundInadequate DNA damage repair promotes aberrant differentiation of mammary epithelial cells. Mammary luminal cell fate is mainly determined by a few transcription factors including GATA3. We previously reported that GATA3 functions downstream of BRCA1 to suppress aberrant differentiation in breast cancer. How GATA3 impacts DNA damage repair preventing aberrant cell differentiation in breast cancer remains elusive. We previously demonstrated that loss of p18, a cell cycle inhibitor, in mice induces luminal-type mammary tumors, whereas depletion of either Brca1 or Gata3 in p18 null mice leads to basal-like breast cancers (BLBCs) with activation of epithelial-mesenchymal transition (EMT). We took advantage of these mutant mice to examine the role of Gata3 as well as the interaction of Gata3 and Brca1 in DNA damage repair in mammary tumorigenesis.

resultsDepletion of Gata3, like that of Brca1, promoted DNA damage accumulation in breast cancer cells in vitro and in basal-like breast cancers in vivo. Reconstitution of Gata3 improved DNA damage repair in Brca1-deficient mammary tumorigenesis. Overexpression of GATA3 promoted homologous recombination (HR)-mediated DNA damage repair and restored HR efficiency of BRCA1-deficient cells. Depletion of Gata3 sensitized tumor cells to PARP inhibitor (PARPi), and reconstitution of Gata3 enhanced resistance of Brca1-deficient tumor cells to PARP inhibitor.

conclusionsThese results demonstrate that Gata3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in mammary tumorigenesis and progression. Our findings suggest that PARP inhibitors are effective for the treatment of GATA3-deficient BLBCs.

Indexed as

Mammary Neoplasms, AnimalPoly(ADP-ribose) Polymerase InhibitorsAnimalsBRCA1 ProteinCell Line, TumorCell Transformation, NeoplasticDNA DamageDNA RepairGATA3 Transcription FactorMiceBRCA1 ProteinBrca1 protein, mouseGata3 protein, mouseGATA3 Transcription FactorPoly(ADP-ribose) Polymerase InhibitorsBRCA1Breast cancerDedifferentiationDNA damageGATA3

Identifiers

PMID38627785
PMCPMC11020915
OpenAlexW4394837059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.